STTK Stock Overview
A clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Shattuck Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.63 |
| 52 Week High | US$11.76 |
| 52 Week Low | US$1.33 |
| Beta | 2 |
| 1 Month Change | -17.96% |
| 3 Month Change | -14.46% |
| 1 Year Change | 160.41% |
| 3 Year Change | -69.43% |
| 5 Year Change | n/a |
| Change since IPO | -60.57% |
Recent News & Updates
Recent updates
Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?
Jun 28
We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
Mar 09Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?
Nov 23Shattuck Labs GAAP EPS of -$0.65 misses by $0.06
Aug 11We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
Jul 26Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 18Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?
Feb 25Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?
Nov 23We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth
Aug 24Shattuck Labs names Abhinav Shukla as chief technical officer
Jun 01Shattuck Labs EPS beats by $0.11, beats on revenue
May 10Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation
May 07Could The Shattuck Labs, Inc. (NASDAQ:STTK) Ownership Structure Tell Us Something Useful?
Mar 08We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely
Jan 12
Shattuck Labs reports Q3 results
Nov 13Shareholder Returns
| STTK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.5% | 0.7% | 1.2% |
| 1Y | 160.4% | 5.0% | 27.7% |
Return vs Industry: STTK exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: STTK exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| STTK volatility | |
|---|---|
| STTK Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: STTK's share price has been volatile over the past 3 months.
Volatility Over Time: STTK's weekly volatility has decreased from 23% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 75 | Taylor Schreiber | www.shattucklabs.com |
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc. Fundamentals Summary
| STTK fundamental statistics | |
|---|---|
| Market cap | US$367.09m |
| Earnings (TTM) | -US$85.08m |
| Revenue (TTM) | US$2.72m |
133.6x
P/S Ratio-4.3x
P/E RatioIs STTK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STTK income statement (TTM) | |
|---|---|
| Revenue | US$2.72m |
| Cost of Revenue | US$73.61m |
| Gross Profit | -US$70.89m |
| Other Expenses | US$14.19m |
| Earnings | -US$85.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.79 |
| Gross Margin | -2,611.12% |
| Net Profit Margin | -3,133.63% |
| Debt/Equity Ratio | 0% |
How did STTK perform over the long term?
See historical performance and comparison